RhumbLine Advisers’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-118,557
| Closed | -$2.54M | – | 4160 |
|
|
2026
Q1 | $2.54M | Buy |
118,557
+6,878
| +6% | +$96.9K | ﹤0.01% | 1734 |
|
|
2025
Q4 | $1.04M | Sell |
111,679
-10,266
| -8% | -$85.8K | ﹤0.01% | 2199 |
|
|
2025
Q3 | $860K | Buy |
121,945
+5,885
| +5% | +$40.5K | ﹤0.01% | 2330 |
|
|
2025
Q2 | $754K | Buy |
116,060
+34,216
| +42% | +$235K | ﹤0.01% | 2394 |
|
|
2025
Q1 | $649K | Buy |
81,844
+6,291
| +8% | +$67.8K | ﹤0.01% | 2397 |
|
|
2024
Q4 | $957K | Sell |
75,553
-1,747
| -2% | -$24.3K | ﹤0.01% | 2275 |
|
|
2024
Q3 | $1.08M | Sell |
77,300
-8,138
| -10% | -$116K | ﹤0.01% | 2233 |
|
|
2024
Q2 | $1.18M | Sell |
85,438
-4,289
| -5% | -$62.8K | ﹤0.01% | 2154 |
|
|
2024
Q1 | $1.48M | Buy |
89,727
+2,293
| +3% | +$34.3K | ﹤0.01% | 2056 |
|
|
2023
Q4 | $1.28M | Sell |
87,434
-1,769
| -2% | -$21.4K | ﹤0.01% | 2138 |
|
|
2023
Q3 | $1.09M | Buy |
89,203
+22,942
| +35% | +$299K | ﹤0.01% | 2154 |
|
|
2023
Q2 | $791K | Buy |
66,261
+22,265
| +51% | +$291K | ﹤0.01% | 2423 |
|
|
2023
Q1 | $588K | Buy |
43,996
+1,043
| +2% | +$20.4K | ﹤0.01% | 2374 |
|
|
2022
Q4 | $924K | Buy |
42,953
+711
| +2% | +$14.6K | ﹤0.01% | 2166 |
|
|
2022
Q3 | $846K | Buy |
42,242
+8,288
| +24% | +$176K | ﹤0.01% | 2233 |
|
|
2022
Q2 | $608K | Buy |
33,954
+14,546
| +75% | +$150K | ﹤0.01% | 2390 |
|
|
2022
Q1 | $193K | Buy |
+19,408
| New | +$256K | ﹤0.01% | 2765 |
|
Other funds holding DAWN
RhumbLine Advisers's DAWN Position: Q2 2026 in Review
RhumbLine Advisers sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 118,557 shares — an estimated $2.54M sold.
RhumbLine Advisers first reported a position in DAWN in Q1 2022 and held it in 17 quarters. The position peaked at $2.54M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- RhumbLine Advisers reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- RhumbLine Advisers sold 118,557 Day One Biopharmaceuticals shares in Q2 2026, an estimated $2.54M.
- RhumbLine Advisers first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 17 quarters.
- RhumbLine Advisers's Day One Biopharmaceuticals position peaked at $2.54M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.